GO
Loading...

Enter multiple symbols separated by commas

Stocks Perrigo Co

More

  • NEW YORK— Mylan NV's shareholders approved the company's hostile pursuit of Perrigo Co. and the generic drugmaker hopes to push ahead with a formal offer soon. Perrigo, which makes over-the-counter medicines, has resisted repeated overtures from Mylan. In April, Mylan raised its offer for Perrigo to $232.23, or about $34.1 billion, in cash and stock.

  • NEW YORK, Aug 6- Generic drugmaker Mylan Inc's chief executive said on Thursday that acquiring Perrigo Co was not a must and that it has other options should Perrigo successfully fend off Mylan's $34 billion hostile offer. However, Mylan CEO Heather Bresch said in an interview that getting the Perrigo deal done remains a top priority and that she still believes...

  • Aug 6- Drugmaker Mylan Inc reported a better-than-expected quarterly profit as it sold more generic drugs in North America, and said it remained committed to its acquisition of Perrigo Co Plc. Mylan, which also raised its full-year earnings forecast, has been pursuing Perrigo since April in an attempt to boost its over-the-counter drug business and extend its...

  • Drugmaker Mylan's quarterly revenue jumps 29 pct Thursday, 6 Aug 2015 | 7:19 AM ET

    Aug 6- Drugmaker Mylan Inc reported a 29 percent jump in quarterly revenue as it sold more generic drugs in North America. The company, which is pursuing smaller rival Perrigo Co Plc, said net profit attributable to shareholders rose to $167.8 million in the second quarter ended June 30, from $125.2 million a year earlier. The company's revenue rose to $2.37...

  • Mylan, whose shares fell 14.5 percent, said it would continue its own unsolicited pursuit of Irish drugmaker Perrigo Co, a maker of over-the-counter consumer and nutritional products and generic topical medicines. Perrigo is one of the few remaining assets out there, "said Morningstar analyst Michael Waterhouse. Other industry analysts expect Mylan will...

  • TEL AVIV, July 27- Teva Pharmaceutical Industries has agreed to buy Allergan Plc's generic drugs business for $40.5 billion in a cash and stock deal that will turn the Israeli company into one of the world's largest pharmaceutical firms. It also will allow Dublin- based Allergan, the third-largest generic drugmaker in the United States, to focus on branded drugs...

  • TEL AVIV, July 27- Teva Pharmaceutical Industries has agreed to buy Allergan Plc's generic drugs business for $40.5 billion in a deal that will turn Teva into one of the top 10 pharmaceutical companies. Allergan's generic business is generally seen as a better fit than Teva's previous target Mylan because it will improve Teva's distribution channels and...

  • July 25- Teva Pharmaceutical Industries Ltd is in advanced talks to buy Allergan Plc's generic drug business following a thus far unsuccessful effort to acquire peer Mylan NV, according to a person familiar with the matter. Jerusalem- based Teva, which has offered to buy Mylan for $40 billion, is now close to an agreement to acquire Dublin- based Allergan's...

  • WASHINGTON, July 14- A proposed merger of the two largest U.S. generic drug makers drew fire on Tuesday from Consumers Union and seven other groups, who asked antitrust enforcers to stop Teva Pharmaceutical Industries Ltd's proposal to purchase Mylan NV, saying it would lead to higher prices and more drug shortages. Meanwhile, Mylan has pressed on with a $34...

  • NEW YORK/ LONDON, June 29- Mergers and acquisitions worldwide in the second quarter of 2015 almost matched the record set in the second quarter of 2007, according to preliminary Thomson Reuters data, as big companies turned to deals to boost their market share. These include Royal Dutch Shell Plc's $70 billion acquisition of British rival BG Group Plc, cable...

  • TEL AVIV, June 24- Drugmaker Mylan NV's chief financial officer John Sheehan said on Wednesday the company would like to join the Tel Aviv Stock Exchange if it succeeds in buying Perrigo Co.. Mylan, which has its primary listing in the United States, has offered to acquire Perrigo for $34 billion. Perrigo's shares have been listed on TASE since it acquired Israeli...

  • Mylan eyes Tel Aviv listing if Perrigo deal goes ahead Wednesday, 24 Jun 2015 | 9:07 AM ET

    TEL AVIV, June 24- Drugmaker Mylan NV's chief financial officer John Sheehan said on Wednesday the company would like to join the Tel Aviv Stock Exchange if it succeeds in buying Perrigo Co.. Mylan, which has its primary listing in the United States, has offered to acquire Perrigo for $34 billion. "Mylan believes that the Israeli market is important to Mylan and the...

  • TEL AVIV, June 23- Mylan NV chief financial officer John Sheehan will arrive in Israel on Wednesday for a meeting with the head of the Tel Aviv Stock Exchange to discuss a possible listing of its shares if it succeeds in buying Perrigo Co, an industry source said. Mylan has offered to acquire Perrigo for $34 billion in an attempt to fend off a bid from Israel's Teva...

  • June 16- Mylan NV's largest stakeholder, Abbott Laboratories, said it would back Mylan's proposed acquisition of Perrigo Co Plc, potentially helping Mylan fend of interest from Teva Pharmaceutical Industries Ltd. Abbott, which has a 14.5 percent stake in Mylan, said on Tuesday that it supported Mylan's "standalone strategy" and believed acquiring Perrigo...

  • Abbott to vote for Mylan's acquisition of Perrigo Tuesday, 16 Jun 2015 | 9:20 AM ET

    June 16- Abbott Laboratories said it would vote its 14.5 percent stake in Mylan NV in favor of Mylan's proposed acquisition of Perrigo Company Plc. Mylan's latest offer for Perrigo, worth $34.1 billion, is widely seen as an attempt to fend off Teva Pharmaceutical Industries Ltd, the world's biggest maker of generic drugs. Abbott, Mylan's largest shareholder, said...

  • AMSTERDAM, June 8- Executives at Israeli drugmaker Teva sent an open letter to takeover target Mylan on Monday, saying they remain committed to a deal and reiterated that Teva's $40 billion takeover proposal would benefit shareholders of both firms. In the letter, addressed to Mylan executive founder Robert Coury, Teva CEO Erez Vigodman and Chairman Yitzhak...

  • Teva discloses 1.35 pct stake in target Mylan Wednesday, 27 May 2015 | 4:42 PM ET

    May 27- Teva Pharmaceutical Industries Ltd disclosed a 1.35 percent interest in Mylan NV, saying the purchase underscored its commitment to buy Mylan as soon as possible. Teva proposed to buy Mylan for $82 per share, or about $43 billion, in cash and stock last month. Mylan rejected the offer saying it "grossly undervalued" the company, setting up a three-way battle...

  • The company has been steadfast in its refusal to combine with Teva and is instead encouraging shareholders to support its own $34 billion unsolicited offer for over-the-counter drugmaker Perrigo Co Plc. Teva said on Tuesday it will move ahead with its plans to acquire Mylan if the Perrigo deal is not completed. Speaking privately to investors this week,...

  • *Alexion offers $225.92 per Synageva share in cash and stock. May 6- Alexion Pharmaceuticals Inc on Wednesday said it agreed to buy Synageva BioPharma Corp for $8.4 billion, more than twice its market value, to expand its offering of potentially high-priced medicines for rare diseases. The medicine, which can cost more than $500,000 per year, generated sales of...

  • INTERVIEW-New-look GSK bets on consumer health spending Wednesday, 6 May 2015 | 7:19 AM ET

    LONDON, May 6- Consumers from New York to New Delhi are digging deeper in their pockets for over-the-counter remedies and health products, a trend GlaxoSmithKline is banking on to help shape the next chapter in its evolution. In the biggest shake-up in its 15- year history, GSK has just sold its cancer drugs to Novartis, while buying the Swiss group's vaccine...